Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. Moreover, ibrutinib-resistant disease is being steadily reported and is associated with dismal clinical outcome (overall survival of 2.9-3.1 months). To understand mechanisms of ibrutinib resistance in WM, we established ibrutinib-resistant in vitro models using validated WM cell lines. Characterization of these models revealed the absence of BTK C481S and CXCR4 WHIM-like mutations. BTK-mediated signaling was found to be highly attenuated accompanied by a shift in PI3K/AKT and apoptosis regulation-associated genes/proteins. Cytotoxicity studies using the AKT inhibitor, MK2206 ± ibrutinib, and the Bcl-2-specific inhibitor, venetoclax ± ibrutinib, demonstrated synergistic loss of cell viability when either MK22016 or venetoclax were used in combination with ibrutinib. Our findings demonstrate that induction of ibrutinib resistance in WM cells can arise independent of BTK C481S and CXCR4 WHIM-like mutations and sustained pressure from ibrutinib appears to activate compensatory AKT signaling as well as reshuffling of Bcl-2 family proteins for maintenance of cell survival. Combination treatment demonstrated greater (and synergistic) antitumor effect and provides rationale for development of therapeutic strategies encompassing venetoclax+ibrutinib or PI3K/AKT inhibitors+ibrutinib in ibrutinib-resistant WM.
INTRODUCTION
Waldenstrom macroglobulinemia (WM), a rare non-Hodgkin lymphoma variant, is characterized by unrestrained clonal proliferation of lymphoplasmacytic cells in the bone marrow and lymphoid tissue (lymph nodes, spleen). Patients usually present with cytopenias, lymphadenopathy and/or hepatosplenomegaly. 1 In addition, WM cells produce and secrete excessive amounts of monoclonal immunoglobulin M (IgM), which can cause hyperviscosity syndrome and its associated complications. Therapeutic strategies have been extrapolated from other low-grade nonHodgkin lymphoma and until very recently no drug had specifically secured approval in WM. 2 Ibrutinib, a first-in-class Brutons tyrosine kinase (BTK) inhibitor, is the first drug to gain Food and Drug Administration approval for treatment of WM and represents a milestone for patients suffering from this malignancy. In a phase II trial, relapsed or refractory WM patients who received ibrutinib demonstrated an overall response rate of 90.5%, with a major response rate of 70.5%. Estimated progression-free and overall survival (OS) at 24 months of treatment was 69.1% (95% confidence interval (CI): 53.2-80.5) and 95.2% (95% CI: 86.0-98.4), respectively. 3 However, no complete remissions were observed, indicating the WM cell's ability to maintain their survival under ibrutinib-induced stress.
Despite the clinical benefit derived by patients treated with ibrutinib, undoubtedly the phenomenon of resistance to its effects is increasingly being reported in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and also WM (malignancies for which ibrutinib is currently approved). [4] [5] [6] [7] [8] [9] [10] [11] Biologically this reflects the malignant tumor clone's ability to survive sustained BTK inhibition and indicates the lack of curative potential at least with ibrutinib monotherapy. Indeed, ibrutinib-resistant disease is now consistently reported with fatal outcome, with median OS of CLL and MCL patients who relapse on ibrutinib being~3.1 and 2.9 months, respectively. 12, 13 Although OS data for postibrutinib relapse WM patients is not yet available, it is anticipated that when these patients relapse (or become refractory to ibrutinib), their survival outcome may follow a similar dismal clinical course. Our laboratory efforts preemptively have tried to address this problem through development of unique models to interrogate the biology of ibrutinib resistance in WM in a quest to become prepared for potential salvage approaches. yet been confirmed in WM patients, and even in CLL and MCL, BTK C481S is not universally noted in all patients who develop ibrutinib resistance. 19, 20 In WM, CXCR4 WHIM-like mutations have been suggested as determinants of response to ibrutinib. However, the observation that 38% of WM patients who are MYD88 L265P+ /CXCR4 WHIM+ exhibit suboptimal response (i.e. less than major response) vs 62% of MYD88 L265P+ /CXCR4
WHIM+ patients who demonstrate major responses suggests that mechanisms other than CXCR4 WHIM-like mutation must account for ibrutinib resistance. 11 Considering ibrutinib is the only approved therapeutic for WM, interrogation of the molecular mechanisms of resistance to ibrutinib in WM is of paramount importance to unveil new therapeutic opportunities in patients who have relapsed or become refractory to ibrutinib therapy. 21 
MATERIALS AND METHODS
Cell lines, cell culture and reagents WM cell lines and their corresponding ibrutinib-resistant clones, developed in our laboratory, were used in experiments. All cell lines were cultured in RPMI-1640 containing 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 μg/ml). Cell viability was always maintained at 490% and was measured by trypan blue exclusion assay using ViCell-XR viability counter (Beckman-Coulter, Indianapolis, IN, USA). RPMI, penicillin, streptomycin, tetramethylrhodamine, methyl ester (TMRM) and fetal bovine serum were purchased from Life technologies (Carlsbad, CA, USA). Ibrutinib, MK2206 and ABT-199 (venetoclax) were purchased from Sellekhem (Houston, TX, USA). Annexin-V/Propidium Iodide Apoptosis Staining Kit was purchased from BD Biosciences (San Jose, CA, USA).
Cell proliferation, viability and apoptosis assays MTS assay (Molecular Probes, ThermoFisher Scientific, Rockford, IL, USA) or the CellTiter Glo Luminescent Cell Assay (Promega, Madison, WI, USA) were used to establish proliferation and viability of tumor cells, under previously reported conditions. 15, 22 Apoptosis was measured by annexin-V and propidium iodide staining of cells followed by flow cytometry analysis. The conditions and method for these assays have been previously described by us. 15 Drug combination synergy, additivity or antagonism were determined using the CompuSyn Software (ComboSyn Inc., Paramus, NJ, USA), which uses the Chou-Talalay principle. 23 Details for this analysis are presented in the Supplementary Material and methods.
Determination of MOMP
Cells were treated with venetoclax for 12 h and assessed for mitochondrial outer membrane permeability (MOMP) using TMRM in a manner similar to that previously reported by us. 15, 22, 24, 25 Cell respirometry assay Mitochondrial oxygen consumption rate was measured using the Seahorse XF96 Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). BCWM.1 and BCWM.1/IR cells were collected by centrifugation (room temperature (RT), 10 min, 200 g) washed two times with custom-made no phenol red containing low-buffered non-bicarbonated Seahorse medium (pH 7.35): powder Dulbecco's modified Eagle's media supplemented with 10 mM glucose, 10 mM pyruvate and 2 mM L-glutamine (all from Sigma-Aldrich, St Louis, MO, USA). Cell counts were adjusted and 2.5 × 10 5 vital cells per well were seeded on Seahorse 96-well plate previously coated with poly-Dlysine-in pentaplicates per each condition. Pelleted cells (room temperature, 1 min, 600 g) were further caped in CO 2 -free incubator for 1 h prior tobefore the experiment. The Seahorse program included a 20 min probe equilibration step followed by a 3 min mix, and 3 min measurement, which was repeated three times before and after each injection. Drugs were injected sequentially in final concentration as follows: 2 μM oligomycin, 1.5 μM carbonyl cyanide-4-phenylhydrazone and combination of rotenone and antimycin A each 0.5 μM (all from Sigma-Aldrich). After completion of the assay, the obtained oxygen consumption rate values were normalized to total protein content. Cells in each well were lysed in RIPA buffer: 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate and 1% NP-40 (all from Sigma-Aldrich) and protein content was determined using the BCA Protein Assay (ThermoFisher Scientific) according to the manufacturer's recommendation. Normalized data were analyzed using Seahorse Wave software and Excel macro file XF Mito Stress Test Report Generator (Agilent Technologies, Santa Clara, CA, USA). Displayed data show mean values and standard error of the mean.
Immunoblot analysis
Western blot was performed for specific cellular protein estimations as reported previously. 25 Total protein extracts were prepared using RIPA lysis buffer alongside 0.2% protease and a phosphatase inhibitor cocktail (Sigma-Aldrich). Supernatant was collected for western blot analyses after centrifugation, and the protein content was measured by BCA protein assay reagent. Twenty micrograms of total protein were then boiled in Laemmli sample buffer, loaded onto 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels and transferred onto a nitrocellulose membrane. Blots were developed using chemiluminescence (ThermoFisher Scientific).
Sanger sequencing of BTK and CXCR4
RNA was isolated from all WM cells, including ibrutinib-resistant cloens, using the miRCURY RNA Isolation Kit (300110; Exiqon, Woburn, MA, USA) and quantified using NanoDrop 3000 (Thermofisher Scientific). Using specific primer sequence for the whole gene, RNA was converted to cDNA by using SuperScript III One Step RT-PCR (12574030; Thermofisher Scientific). Primers for BTK and CXCR4 are included in the Supplementary Materials and methods.
Cell surface antigen analysis
For staining of cell surface markers, WM cells were washed two times with cold phosphate-buffered saline (PBS) and suspended in 300 μl of binding buffer (PBS solution with 2% fetal bovine serum). Cells were divided into three tubes: unstained, isotype control and those with antibody against CD19 (MACS Miltenyi Biotech, San Diego CA, USA), κ-light-chain and λ-light-chain (Invitrogen, Life Technologies, Carlsbad, CA, USA). Five microliters of the respective antibody was added and cells were incubated for 30 min at room temperature. Tumor cells were washed two times with cold PBS and suspended in 100 μl of 4% paraformaldehyde in PBS solution (ThermoFisher Scientific), followed by analysis using a BD Accuri C6 Flow Cytometer (Agilent Technologies, Santa Clara, CA, USA). FCS Express 4 (De Novo Softwares, Glendale, CA, USA) was used to analyze the data.
Cell cycle analysis
Cells were serum starved for 4 h and treated with the drug for 12 h under normal culture conditions (10% fetal bovine serum). One million cells per sample were washed two times with cold PBS (SH30256; GE Healthcare Life Sciences, Logan, UT, USA). Cells were later resuspended in 0.5% glucose solution in PBS; later, they were fixed by 5 ml of 70% ice-cold alcohol and incubated at − 20°F overnight. Cells were spun down at 2500 r.p.m. for 5 min to decant the alcohol and then washed two times with 0.1% Triton X-100 solution. Cells were resuspended in 1 ml of PBS containing RNAase (100 μg/ ml) and propidium iodide stain (50 μg/ml) solution (BD Biosciences) and incubated in water bath (37°C) for 30 min. With a pipette, cells were resuspended and read on an Accuri C6 Flow Cytometer (BD Biosciences) at slow speed. Samples were analyzed using FCS Express 4 (De Novo Softwares).
Human IgM measurement
To quantify human IgM secreted in the sera of WM cells, we used the E-80M Human IgM ELISA Kit (Immunology Consultants Laboratory, Portland, OR, USA) according to the manufacturer's instructions.
Digital mRNA expression profiling (nCounter NanoString platform)
Focused mRNA profiling and informatics analysis was carried out using the NanoString nCounter Assay (NanoString, Seattle, WA, USA) to determine the expression of select cancer genes in WM cells treated with dimethyl sulfoxide (DMSO) or ibrutinib, as described previously. 22, 25, 26 Whole-exome sequencing DNA samples from BCWM.1, MWCL-1 and RPCI-WM1 and their respective ibrutinib-resistant derivatives (BCWM.1/IR, MWCL-1/IR, RPCI-WM1/IR) were captured using SureSelect Human All Exon V5+UTRs from Agilent Technologies. Additional details are described in the Supplementary Materials and methods. Table S2 ). Cell cycle analysis by flow cytometry at 12 h showed that while ibrutinib treatment of WT WM cells retarded cell growth/division (as is consistent with the drugs known cytostatic effect), ibrutinib- resistant cells (after 48 h washout) remained in a growth-arrested state where 490% of cells were in the G1/G2 phase of the cell cycle (Figure 2b ). Light microscopy showed that ibrutinib-resistant cells tended to cluster, and phenotypically were larger in size and less uniform in shape, confirming the inability of these cells to complete the G1 phase (Figure 2c ). The G1 phase of the cell cycle has been shown to be associated with changes in the mitochondria and increased respiration. 28 This led us to examine mitochondrial welfare and bioenergetics, comparing mitochondrial respiration in parental and resistant cells. Using the Seahorse XF96 Flux Analyzer and examining BCWM.1 and its corresponding ibrutinib-resistant subclone (BCWM.1/IR), we found the resistant cells to have an overall increased oxygen consumption rate compared with parental cells (Figure 2d ). Basal respiration in the resistant cells was increased by 30%. A similar level of increase was found in mitochondrial ATP production supporting the observation of increased mitochondrial utilization in these cells. Moreover, carbonyl cyanide-4-phenylhydrazone treatment revealed elevation in maximal respiration that reflects higher spare respiratory capacity of mitochondria in BCWM.1/IR cells as compared with parental BCWM.1 cell (Figure 2e ). These findings suggest higher capability of ibrutinibresistant cells to maintain and sustain increased mitochondrial demand under stress conditions. Moreover, we noted more than 50% increase in non-mitochondrial oxygen consumption/respiration, suggesting the ability of mitochondria of ibrutinib-resistant WM cells to adapt in a pro-oxidative environment, thus making them more resilient toward stress-associated cytoxicity.
We also examined IgM secretion from the ibrutinib-resistant cells and found it to be significantly decreased in all resistant clones (after 48 h washout and reintroduction to ibrutinib) compared with WT cells (before and after treatment with ibrutinib) (Figure 2f ). Consistent with this effect, we also observed reduced cell surface expression of cognate Ig-light-chain receptors on ibrutinib-resistant WM cells (Figure 2g) . Altogether, these data indicate the altered proliferative capacity yet tenacity of ibrutinibresistant cells to maintain survival under selective pressure from ibrutinib, through mechanisms independent of BTK C481S or CXCR4 WHIM-like mutations.
BCR signaling is attenuated in ibrutinib-resistant WM cells without consequence to tumor cell viability and growth As ibrutinib abrogates BTK-mediated signaling that is propagated through the B-cell receptor (BCR) hub, 5, 29 we examined this signaling pathway in all WM cell lines. Ibrutinib treatment (1 μM) of WT WM cell lines markedly decreased phospho (p)BTK, pPLCγ2 and pSYK levels, demonstrating drug-target engagement and inhibition of BCR signaling as would be anticipated (Figure 3a) . Contrastingly, in ibrutinib-resistant derivatives, we noted constitutively decreased pBTK, pPLCγ2 and pSYK protein levels-with the cells retaining 490% viability. Interestingly, after 48 h washout and culture in ibrutinib-free media, we observed marked upregulation of pBTK, pPLCγ2 and pSYK, but this did not impact ibrutinib-resistant cell viability ( Figure 3b ). As CD19 can complex with the BCR receptor to enhance signaling, 30 we examined CD19 surface receptor expression by flow cytometry and observed significant decrease in ibrutinib-resistant cells compared with WT cells (Figure 3c ). Taken together, these data suggested to us that ibrutinib-resistant WM cells shift survival and growth dependence away from BCR/BTK-mediated signaling and engage alternative pathway(s) to maintain viability.
Phospho-AKT expression in ibrutinib-resistant cells is upregulated and its pharmacologic inhibition results in decreased tumor cell survival and apoptosis Dysfunctional AKT signaling has been reported to contribute to ibrutinib insensitivity in CXCR4 WHIM + WM cells. 9 As such, we investigated the relevance of AKT in our CXCR4
WHIM -negative ibrutinib-resistant WM cells. Targeted transcriptome analysis showed expression of genes associated with AKT signaling (such as MET and WNT10B) to be increased in RPCI-WM1/IR cells (Supplementary Table S1 ). Indeed, we had noted that after treatment of WT BCWM.1 cells with ibrutinib, phosphorylation of AKT (at Thr308 and Ser473) was markedly increased (Figure 4a , left panel set). And, this effect was prominent at baseline in BCWM.1/ IR cells with a slight increase in pAKT Thr308 noted after 48 h washout of cells and reincubation with ibrutinib ( Figure 4a , left panel set). Contrastingly, RPCI-WM1 cells, which display some growth insensitivity towards ibrutinib at baseline compared with BCWM.1 and MWCL-1 cells (Figure 1a) , were noted to constitutively express pAKT at baseline, with no change in pATK following exposure to ibrutinib (Figure 4a, right panel set) . Similarly, RPCI- In a similar manner, ibrutinib-resistant WM clones were also probed with anti-BTK/pBTK, anti-SYK/pSYK, anti-PLCγ2/pPLCγ2 and GAPDH antibodies. While immunobot analysis showed very low pBTK, pSYK or pPLCγ2 protein levels in ibrutinib-resistant clones (kept in ibrutinib-containing media at 490% viability), protein levels increased after washout of cells (after 48 h in ibrutinib-free media). Notably, viability of ibrutinib-resistant clones-before or after washout, was not impacted. (c) All WM cell lines were incubated with anti-CD19 antibody followed by flow cytometry. Compared to WT parental cells, BCWM.1/IR and MWCL-1/IR cells showed reduced surface expression of CD19. RPCI-WM1 is known to be CD19-and this was also noted in RPCI-WM1/IR cells. (Figure 4a) . However, when cells were treated concurrently with ibrutinib and MK2206, we noted marked reduction in pBTK and nearly complete loss of pAKT, which was associated with more robust cleavage of PARP-1 (Figure 4a ). Overall, it is important to note that the minor differences noted in protein levels of different signaling molecules between the various cell line models is expected given our prior report/analysis on the variable state of generation of these cell lines (i.e. relapse/refractory vs untreated). 33, 34 Observing that concurrent BTK and AKT inhibition could result in potentially more programmed cell death, we treated BCWM.1 and RPCI-WM1 (and their respective ibrutinib-resistant derivatives) with different concentrations of MK2206, ibrutinib or MK2206+ibrutinib for 48 h and assessed the viability. As expected, the combination of both drugs reduced WT and ibrutinib-resistant cell viability significantly more so than either ibrutinib or MK2206 alone (Figure 4b Modulation of Bcl-2 expression as a function of resistance induction resulting in sensitivity to venetoclax treatment In addition to compensatory AKT signaling, we investigated other potential mechanisms for ibrutinib resistance in WM cells. Deferred apoptosis is a hallmark of many B-cell malignancies associated with drug resistance; 15, 25, 35, 36 as such, we examined expression of apoptotic regulators in our transcriptome expression data set. This analysis revealed modulation of several genes known to regulate apoptotic machinery such as BMI1, GNAS, IL8 Tables S1 and 2 ). Thus, we immunoblotted directly for apoptosis effectors; anti-(Bcl-2, Mcl-1, A1) and proapoptotic (Bax, Bak, Bim and PUMA) Bcl-2 family members in WT and ibrutinib-resistant clones and observed increased Bcl-2 and Mcl-1 in the latter, whereas proapoptotic proteins displayed more variable expression patterns (Figure 5a ). This demonstrated that dysfunctional Bcl-2 interactions may have a role in maintaining ibrutinib-resistant cell survival. Next, we investigated anti-WM activity of the Bcl-2-specific BH3 mimetic, venetoclax (ABT-199, recently Food and Drug Administration-approved for treatment of 17p deletionpositive relapsed/refractory CLL), [37] [38] [39] in WT and ibrutinib-resistant derivatives. Modeling studies of venetoclax revealed its occupancy at the P2 and P4 pockets in the BH3 groove of the Bcl-2 protein and stabilization at the Asp103 residue in particular, which is critical for specificity towards Bcl-2 (Figure 5b ). WT and ibrutinibresistant WM cells were treated with increasing concentrations of venetoclax for 48 h and cell proliferation was measured. Comparable activity of venetoclax was noted in WT and ibrutinib-resistant cells alike, with the exception of MWCL-1/IR cells, which showed greater growth inhibition compared with MWCL-1 parental cells (IC 50 5.1 vs 7.5 μM, respectively) (Figure 5c ). Bcl-2 binds and sequesters proapoptotic BH3 proteins; interference of this dynamic results in Bax/Bak dimerization, mitochondrial pore formation and induction of apoptosis. 40 Thus, we examined MOMP in WT and ibrutinib-resistant WM cells before and after venetoclax treatment. As anticipated, venetoclax compromised mitochondrial function in both WT and ibrutinib-resistant WM cells by increasing MOMP (Figure 5d ), which was associated with induction of apoptosis as determined by annexin-V/PI staining (Figure 5e ). Furthermore, (mitochondrial-mediated) programmed cell death in venetoclax-treated cells was confirmed by the presence of PARP-1 cleavage and cleaved caspase-3 (Figure 5f ).
Venetoclax synergistically enhances the antiproliferative effects of ibrutinib Drug combination therapy produces enhanced antitumor effect and counters drug resistance. 41 We addressed the question of whether concurrently inhibiting Bcl-2 (with venetoclax) and BTK (with ibrutinib) could induce cytotoxicity in WM cells and overcome ibrutinib-resistant WM cell insensitivity to single agent ibrutinib. Two isogenic WM cell line pairs were treated with sub-IC 50 concentrations of venetoclax (V), ibrutinib (I) or venetoclax +ibrutinib (V+I) for 48 h and viability was assessed thereafter. In BCWM.1 and BCWM.1/IR cells, the combination of V+I synergistically reduced tumor cell viability; significantly more so than either V or I alone at a combination index of 0.03 and 0.21, respectively (Figure 6a ). Isobologram analysis of BCWM.1/IR cells demonstrated synergistic cytotoxic activity of V+I in 6/6 combinations (represented by blue circles) (Figure 6b ). In the RPCI-WM1 cell line and its ibrutinib-resistant derivative, the combination of V +I also synergistically reduced tumor cell viability (combination index of 0.48 and 0.80, respectively), an effect more notable than when cells were treated with V or I alone were used in ibrutinibresistant clones (Figure 6c ). Isobologram analysis of RPCI-WM1/IR cells showed that 2/6 combinations displayed synergistic cytotoxic activity (represented by blue circles) (Figure 6d ). Taken in concert, our investigations reveal that altered Bcl-2 family protein expression sustains proliferation in the ibrutinib-resistant WM cells and that venetoclax induces ibrutinib-resistant cell apoptosis (see Figures 5e and f) . Moreover, combination treatment of these cells with venetoclax plus ibrutinib results in enhanced loss in viability of ibrutinib-resistant cells.
DISCUSSION
Ibrutinib resistance represents a unique challenge due to its association with a poor clinical outcome. 12, 13 Overall, biological understanding of how ibrutinib resistance occurs in WM remains limited. Mechanisms of resistance in other B-cell cancers are reported to be associated with ibrutinib-binding site mutations in BTK, 6, 8 whereas in WM, CXCR4 WHIM-like mutations have been reported to correlate with ibrutinib insensitivity in a limited number of cases. 11 As such, the optimal therapeutic strategies to extend clinical remission in patients who have become refractory to ibrutinib are unclear and remain an active area of investigation. To this end, we dedicated our efforts towards establishment of preclinical WM models to study the phenomenon of ibrutinib resistance as is observed clinically-where chronic exposure to ibrutinib over an extended time leads to outgrowth of tumor clones that can maintain proliferative potential under ibrutinibinduced stress.
Characterization of ibrutinib-resistant clones revealed the absence of BTK C481S or CXCR4 WHIM-like mutations. A C481S mutation has been shown to disrupt covalent (irreversible) binding of ibrutinib to BTK and instead permits for a reversible binding interaction, limiting the drugs effect by nearly 25-fold. 6 The absence of a C481S anomaly in our resistant models implied that ), were inhibited by ibrutinib, indicating that drug binding is intact and BCR signaling is abrogated. And, this effect (BCR signalosome phosphorylation status) was reversed when resistant cells were washed out and grown in ibrutinib-free media. In either condition, ibrutinibresistant cells remained viable with stable growth kinetics, indicating to us that in these cells BTK-mediated signaling was not a primary driver of disease. We also noted decreased IgM secretion in the sera of ibrutinib-resistant cells. It would appear that in this drug-resistant state, the emphasis of the tumor cells is more towards survivability and transitioning to an 'oligoseceretory phase'. Clinically this is noted also in patients with plasma cell malignancies, whereby with increasing resistance to therapeutics the cell can eventually evolve into a non-secretory/ oligosecretory phase.
In addition to BTK, we also probed for CXCR4 WHIM-like mutations, which in WM have been shown to decrease CXCR4 receptor internalization, thereby allowing continuous signaling and downstream activation of ERK and AKT, leading to sustained WM cell proliferation/survival. 4 However, the role of AKT and its relevance in WT CXCR4 ibrutinib-resistant WM is unclear. While pAKT was effectively downregulated with MK2206 treatment alone in all WM cells tested herein, this did not translate to a significant loss of viability in WT or ibrutinib-resistant RPCI-WM1/IR cells-and could potentially just be a function of increased basal AKT activity in these cells. However, combined BTK and AKT inhibition induced a significant decrease in RPCI-WM1 and RPCI-WM1/IR cell viability, suggesting that the protective role of AKT could be overcome with concurrent targeting of BTK with ibrutinib (at sub-IC 50 concentrations). Further studies are needed to explicate the role of AKT in CXCR4 WHIM-like -negative ibrutinib-resistant WM and novel, clinically relevant inhibitors that target upstream of AKT, that is, PI3K isoforms (idelalisib, duvelesib) may hold greater anti-WM potential when combined with ibrutinib.
In conjunction with growth-stimulating signaling pathways such as those propagated by AKT/ERK/NFKB activation, 42 WM cell survival is intricately supported by malfunctions in initiation of apoptosis through dysregulated expression of Bcl-2 family proteins. 15, 25, 43 Interestingly, AKT and Bcl-2 are directly linked, where studies by Pugazhenthi et al. 44 have shown that AKT activates the transcription factor CREB (cAMP response elementbinding protein), which binds to the Bcl-2 promoter region and positively regulates its expression. Whether upregulation of Bcl-2 in ibrutinib-resistant WM is related to CREB and AKT is currently being examined by us. Nevertheless, we have previously shown the utility of disrupting proapoptotic Bcl-2 protein interactions in CLL, WM and multiple myeloma and that this functional interference results in malignant cell death or resensitization (or heightened sensitivity) of tumor cells towards other therapeutics. 15, 25, 35, 40, [45] [46] [47] [48] [49] [50] [51] Indeed, this observation also held true for CXCR4
WHIM-like -negative ibrutinib-resistant WM cells, where the Bcl-2-specific BH3 mimetic, venetoclax, decreased ibrutinibresistant WM cell viability and induced apoptosis as a single agent. Our investigations further highlighted that concomitant disruption of BTK and Bcl-2 with sub-IC 50 doses of ibrutinib and venetoclax, respectively, synergistically induce tumor cell lethality in WT and ibrutinib-resistant cells. These data are in line with observations by Cao et al. 43 in WM, whereas we are the first to demonstrate the utility of combined Bcl-2 and BTK inhibition in ibrutinib-resistant WM cells in which neither BTK C481S nor CXCR4 WHIM-like mutations are responsible for drug resistance. The rationale for Bcl-2 plus BTK inhibition is further supported by preclinical studies in CLL 52 and MCL; 53 the latter where the combination of venetoclax and ibrutinib is being investigated in two separate phase clinical trials (NCT02419560, phase I study; NCT02471391, phase II study).
In conclusion, we report on the development of novel ibrutinibresistant WM cell lines, which exhibit decreased survival dependency on BTK-mediated signaling. These models all lack ibrutinib-binding site (BTK Cys481) mutations as well as CXCR4 WHIM-like mutations, providing new insight into mechanism underpinning ibrutinib resistance independent of these aberrations. Focused transcriptome analysis combined with protein profiling revealed AKT and Bcl-2-associated pathways may have a role in maintaining survival of ibrutinib-resistant WM cells. In vitro efficacy and mechanistic analysis confirmed reliance on both pathways and suggests that drug combination strategies encompassing BTK+AKT/PI3K inhibition or BTK+Bcl-2 inhibition can potentially overcome ibrutinib resistance in WM. Finally, our observations are unique as they feature previously unknown mechanisms directing resistance to ibrutinib in WM cells and provide rationale for potential combination therapeutic strategies to address this clinical problem in patients with WM.
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